Global Markets Direct’s, ‘Idiopathic (Essential) Hypertension – Pipeline Review, H2 2015′, provides an overview of the Idiopathic (Essential) Hypertension’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic (Essential) Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic (Essential) Hypertension and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Idiopathic (Essential) Hypertension
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Idiopathic (Essential) Hypertension and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Idiopathic (Essential) Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Idiopathic (Essential) Hypertension pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Idiopathic (Essential) Hypertension
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Idiopathic (Essential) Hypertension pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Idiopathic (Essential) Hypertension Overview 8
Therapeutics Development 9
Pipeline Products for Idiopathic (Essential) Hypertension - Overview 9
Pipeline Products for Idiopathic (Essential) Hypertension - Comparative Analysis 10
Idiopathic (Essential) Hypertension - Therapeutics under Development by Companies 11
Idiopathic (Essential) Hypertension - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Idiopathic (Essential) Hypertension - Products under Development by Companies 15
Idiopathic (Essential) Hypertension - Companies Involved in Therapeutics Development 16
Bayer AG 16
Chong Kun Dang Pharmaceutical Corp. 17
Eli Lilly and Company 18
HanAll Biopharma Co., Ltd. 19
Jiangsu Hengrui Medicine Co., Ltd. 20
Lee's Pharmaceutical Holdings Limited 21
PhaseBio Pharmaceuticals, Inc. 22
Quantum Genomics SA 23
Sun Pharma Advanced Research Company Ltd. 24
Takeda Pharmaceutical Company Limited 25
TSH Biopharm Corporation Limited 26
Idiopathic (Essential) Hypertension - Therapeutics Assessment 27
Assessment by Monotherapy Products 27
Assessment by Combination Products 28
Assessment by Target 29
Assessment by Mechanism of Action 31
Assessment by Route of Administration 33
Assessment by Molecule Type 35
Drug Profiles 37
(amlodipine besylate + azilsartan medoxomil + hydrochlorothiazide) - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
(amlodipine besylate + candesartan cilexetil) - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
(amlodipine besylate + hydrochlorothiazide + losartan potassium) - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
(atorvastatin calcium + losartan potassium) - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
(nifedipine + candesartan cilexetil) - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
azilsartan medoxomil - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
carvedilol phosphate ER - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
carvedilol phosphate SR - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CRTA-04 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
LY-2623091 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
PB-1046 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
PB-1120 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
QGC-001 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
rostafuroxin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Idiopathic (Essential) Hypertension - Recent Pipeline Updates 55
Idiopathic (Essential) Hypertension - Dormant Projects 60
Idiopathic (Essential) Hypertension - Product Development Milestones 62
Featured News & Press Releases 62
Jun 12, 2013: Lee's Pharma Enrolls First Patient In Phase IIb Clinical Trial Of Rostafuroxin In Italy 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64

List of Tables

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2015 9
Number of Products under Development for Idiopathic (Essential) Hypertension - Comparative Analysis, H2 2015 10
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Comparative Analysis by Early Stage Development, H2 2015 14
Products under Development by Companies, H2 2015 15
Idiopathic (Essential) Hypertension - Pipeline by Bayer AG, H2 2015 16
Idiopathic (Essential) Hypertension - Pipeline by Chong Kun Dang Pharmaceutical Corp., H2 2015 17
Idiopathic (Essential) Hypertension - Pipeline by Eli Lilly and Company, H2 2015 18
Idiopathic (Essential) Hypertension - Pipeline by HanAll Biopharma Co., Ltd., H2 2015 19
Idiopathic (Essential) Hypertension - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H2 2015 20
Idiopathic (Essential) Hypertension - Pipeline by Lee's Pharmaceutical Holdings Limited, H2 2015 21
Idiopathic (Essential) Hypertension - Pipeline by PhaseBio Pharmaceuticals, Inc., H2 2015 22
Idiopathic (Essential) Hypertension - Pipeline by Quantum Genomics SA, H2 2015 23
Idiopathic (Essential) Hypertension - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015 24
Idiopathic (Essential) Hypertension - Pipeline by Takeda Pharmaceutical Company Limited, H2 2015 25
Idiopathic (Essential) Hypertension - Pipeline by TSH Biopharm Corporation Limited, H2 2015 26
Assessment by Monotherapy Products, H2 2015 27
Assessment by Combination Products, H2 2015 28
Number of Products by Stage and Target, H2 2015 30
Number of Products by Stage and Mechanism of Action, H2 2015 32
Number of Products by Stage and Route of Administration, H2 2015 34
Number of Products by Stage and Molecule Type, H2 2015 36
Idiopathic (Essential) Hypertension Therapeutics - Recent Pipeline Updates, H2 2015 55
Idiopathic (Essential) Hypertension - Dormant Projects, H2 2015 60
Idiopathic (Essential) Hypertension - Dormant Projects (Contd...1), H2 2015 61

List of Figures

Number of Products under Development for Idiopathic (Essential) Hypertension, H2 2015 9
Number of Products under Development by Companies, H2 2015 11
Comparative Analysis by Late Stage Development, H2 2015 12
Comparative Analysis by Clinical Stage Development, H2 2015 13
Assessment by Monotherapy Products, H2 2015 27
Assessment by Combination Products, H2 2015 28
Number of Products by Top 10 Targets, H2 2015 29
Number of Products by Stage and Top 10 Targets, H2 2015 29
Number of Products by Top 10 Mechanism of Actions, H2 2015 31
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 31
Number of Products by Top 10 Routes of Administration, H2 2015 33
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 33
Number of Products by Molecule Types, H2 2015 35
Number of Products by Stage and Molecule Types, H2 2015 35